GPR55 and the vascular receptors for cannabinoids.
CB1 and CB2 receptors mediate most responses to cannabinoids but not some of the cardiovascular actions of endocannabinoids such as anandamide and virodhamine, or those of some synthetic agents, like abnormal cannabidiol (abn-cbd). These agents induce vasorelaxation which is antagonised by rimonabant but only at high concentrations relative to those required to block CB1 receptors. Vasorelaxation to anandamide is sensitive to Pertussis toxin (though that to abn-cbd is not), and so is thought to be mediated by a G protein-coupled receptor through Gi/o. An orphan receptor, GPR55, apparently a cannabinoid receptor, is activated by abn-cbd, but is not the receptor mediating vasorelaxation to this agent, as the response persists in vessels from GPR55 knockout mice. However, the activity of anandamide in GPR55 knockout mice is not yet reported and so the role of GPR55 as a cannabinoid receptor mediating vascular responses has yet to be finalised.
Hiley
C R
CR
Department of Pharmacology, University of Cambridge, Cambridge, UK. crh1@cam.ac.uk
Kaup
S S
SS
D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled / Q000819:agonists* / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects
D002186:Cannabinoids; C524885:GPR55 protein, human; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled
Mol Pharmacol. 2003 Mar;63(3):699-705
12606780
Pharmacol Rev. 2002 Jun;54(2):161-202
12037135
Br J Pharmacol. 2004 Jun;142(3):435-42
15148250
Br J Pharmacol. 1997 Dec;122(8):1573-84
9422801
Br J Pharmacol. 1998 Oct;125(3):533-41
9806337
Hypertension. 1999 Jan;33(1 Pt 2):429-34
9931142
Brain Res Mol Brain Res. 1999 Feb 5;64(2):193-8
9931487
Eur J Pharmacol. 2005 Jan 10;507(1-3):211-21
15659311
Br J Pharmacol. 2005 Jun;145(4):514-26
15821751
Trends Pharmacol Sci. 2006 Jan;27(1):1-4
16318877
Chem Biol Drug Des. 2006 Mar;67(3):252-3
16611220
Br J Pharmacol. 2007 Nov;152(5):825-31
17704827
Br J Pharmacol. 2003 Apr;138(7):1320-32
12711633
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14136-41
10570211
Br J Pharmacol. 2002 Mar;135(5):1191-8
11877326
Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H2046-54
12003810